Skip to main content

Vascular Disorders and Anomalies

  • Chapter
  • First Online:
Therapy in Pediatric Dermatology
  • 1377 Accesses

Abstract

Vascular tumors are distinguished from vascular malformations by the presence of mitosis, or increased endothelial turnover. Vascular tumors can be benign, locally aggressive, or malignant. Infantile hemangiomas, the most prevalent vascular tumor, are largely benign entities, but can be functionally and cosmetically impairing if not treated in a timely manner. This chapter addresses infantile hemangiomas, vascular tumors with serious consequences (Kasabach-Merritt phenomenon and multifocal lymphangioendotheliomatosis with thrombocytopenia), and common benign tumors (pyogenic granulomas and angiofibromas).

Vascular malformations are static lesions present at birth, and are classified based upon the type of blood vessels that are involved, and as simple (one vessel type) or combined (two or more vascular malformations in one lesion). They are typically noted at birth, grow in proportion with the patient, and consist of abnormal vessels; some are associated with other anomalies such as overgrowth or leptomeningeal malformations, which, based upon their location or exam, may prompt additional workup and treatment. For patients with complex or combined vascular malformations, a combination of the above techniques is often used, depending on malformation location, size, and morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dasgupta R, Fishman SJ. ISSVA classification. Semin Pediatr Surg. 2014;23(4):158–61.

    Article  PubMed  Google Scholar 

  2. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46.

    Article  PubMed  Google Scholar 

  4. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131(6):e1739–47.

    Article  PubMed  Google Scholar 

  5. Bennett ML, Fleischer Jr AB, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208–13.

    Article  CAS  PubMed  Google Scholar 

  6. Drolet BA, Trenor 3rd CC, Brandão LR, Chiu YE, Chun RH, Dasgupta R, et al. Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma. J Pediatr. 2013;163(1):285–91.

    Article  PubMed  Google Scholar 

  7. Esparza EM, Deutsch G, Stanescu L, Weinberger E, Brandling-Bennett HA, Sidbury R. Multifocal lymphangioendotheliomatosis with thrombocytopenia: phenotypic variant and course with propranolol, corticosteroids, and aminocaproic acid. J Am Acad Dermatol. 2012;67(1):e62–4.

    Article  PubMed  Google Scholar 

  8. Lee J, Sinno H, Tahiri Y, Gilardino MS. Treatment options for cutaneous pyogenic granulomas: a review. J Plast Reconstr Aesthet Surg. 2011;64(9):1216–20.

    Article  PubMed  Google Scholar 

  9. Bae-Harboe YS, Geronemus RG. Targeted topical and combination laser surgery for the treatment of angiofibromas. Lasers Surg Med. 2013;45(9):555–7.

    Article  PubMed  Google Scholar 

  10. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159(2):473–5.

    Article  CAS  PubMed  Google Scholar 

  11. Haemel AK, O’Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146(7):715–8.

    Article  PubMed  Google Scholar 

  12. Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med. 1981;1(3):263–76.

    Article  CAS  PubMed  Google Scholar 

  13. Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med. 2012;366(4):384–6.

    Article  CAS  PubMed  Google Scholar 

  14. Margolin JF, Soni HM, Pimpalwar S. Medical therapy for pediatric vascular anomalies. Semin Plast Surg. 2014;28(2):79–86.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Diana H. Lee .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lee, D.H., Hawryluk, E.B. (2017). Vascular Disorders and Anomalies. In: Teng, J., Marqueling, A., Benjamin, L. (eds) Therapy in Pediatric Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-43630-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43630-2_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43628-9

  • Online ISBN: 978-3-319-43630-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics